2,4,6-TMPEA-NBOMe

2,4,6-TMPEA-NBOMe
Clinical data
Other namesψ-2C-O-NBOMe; 26O-NBOMe; NBOMe-TMPEA-6; N-(2-Methoxybenzyl)-2,4,6-trimethoxyphenethylamine
Routes of
administration		Oral, intranasal[1][2]
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • N-[(2-methoxyphenyl)methyl]-2-(2,4,6-trimethoxyphenyl)ethan-1-amine
Chemical and physical data
FormulaC19H25NO4
Molar mass331.412 g·mol−1
3D model (JSmol)
  • COc1cc(OC)c(c(c1)OC)CCNCc1ccccc1OC
  • InChI=1S/C19H25NO4/c1-21-15-11-18(23-3)16(19(12-15)24-4)9-10-20-13-14-7-5-6-8-17(14)22-2/h5-8,11-12,20H,9-10,13H2,1-4H3
  • Key:NTLHTSWPAAMHIC-UHFFFAOYSA-N

2,4,6-TMPEA-NBOMe, also known as ψ-2C-O-NBOMe or 26O-NBOMe as well as N-(2-methoxybenzyl)-2,4,6-trimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, ψ-PEA, and N-benzylphenethylamine (NBOMe) families.[1][2][3][4][5] It is the NBOMe derivative of ψ-2C-O (2,4,6-TMPEA).[5] The drug is said to produce psychedelic effects such as visuals.[1][2] It has been found to act as a potent serotonin 5-HT2A receptor partial agonist, with an EC50Tooltip half-maximal effective concentration of 1.7 nM and an EmaxTooltip maximal efficacy of 49%.[3][4] 2,4,6-TMPEA-NBOMe was first described in the scientific literature in 2009.[3][4] Subsequently, it was encountered as a novel designer drug in Russia in 2015.[5][1][2] The drug is a controlled substance in Canada under phenethylamine blanket-ban language.[6]

See also

References

  1. ^ a b c d "2,4,6-TMPEA-NBOMe". AIPSIN (in Russian). Retrieved 1 January 2026.
  2. ^ a b c d "2,4,6-TMPEA-NBOMe". AIPSIN (in Russian). Retrieved 1 January 2026.
  3. ^ a b c Silva M (2009). Theoretical study of the interaction of agonists with the 5-HT2A receptor (Ph.D.). Universität Regensburg. Table 5.1: Agonistic potency (pEC50) and intrinsic activity (Emax) of 5-HT2AR partial agonistic arylethylamines (indole, methoxybenzene and quinazolinedione derivatives) used in the study. [...]
  4. ^ a b c Silva ME, Heim R, Strasser A, Elz S, Dove S (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor". Journal of Computer-Aided Molecular Design. 25 (1): 51–66. doi:10.1007/s10822-010-9400-2. PMID 21088982.
  5. ^ a b c Shevyrin V, Kupriyanova O, Lebedev AT, Melkozerov V, Eltsov O, Shafran Y, et al. (October 2016). "Mass spectrometric properties of N-(2-methoxybenzyl)-2-(2,4,6-trimethoxyphenyl)ethanamine (2,4,6-TMPEA-NBOMe), a new representative of designer drugs of NBOMe series and derivatives thereof". Journal of Mass Spectrometry. 51 (10): 969–979. Bibcode:2016JMSp...51..969S. doi:10.1002/jms.3808. PMID 27388323.
  6. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.